Dustin Nickerson
Nurse Practitioner · Phoenix, AZNPI 1760988224
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 89.9% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2024 at $28,272 and has fallen 90.0% since, to $2,827 in 2025. Among nurse practitioner clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 283 payments — averaging $137.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$35K
- Bayer$775
- Amgen$382
- Otsuka America Pharmaceutical, Inc.$238
- OPKO Pharmaceuticals, LLC$216
- Vifor Pharma, Inc.$211
- plus $2K from 26 others
What the payments were for
- Consulting fees$9,00023%
- Speaking & faculty fees$18,25047%
- Travel & lodging$5,79315%
- Food & beverage$5,62714%
- Education$1961%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 93 | $34,924 |
| Bayer | 49 | $775 |
| Amgen | 22 | $382 |
| Otsuka America Pharmaceutical, Inc. | 11 | $238 |
| OPKO Pharmaceuticals, LLC | 11 | $216 |
| Vifor Pharma, Inc. | 11 | $211 |
| GSK | 10 | $182 |
| Boehringer Ingelheim | 10 | $175 |
| Travere Therapeutics, Inc. | 6 | $152 |
| Calliditas Therapeutics US Inc. | 6 | $145 |
| Baxter Healthcare | 2 | $139 |
| Akebia Therapeutics Inc | 6 | $131 |
| Lilly USA, LLC | 6 | $125 |
| Nxstage Medical, Inc. | 1 | $124 |
| Aurinia Pharma U.S., Inc. | 6 | $121 |
| Shield Therapeutics Inc | 1 | $108 |
| Vantive US Healthcare LLC | 1 | $105 |
| Novartis | 5 | $93 |
| Daiichi Sankyo Inc. | 5 | $80 |
| Ardelyx, Inc. | 4 | $73 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $69 |
| Abbott | 2 | $43 |
| Mallinckrodt Hospital Products Inc. | 1 | $37 |
| Johnson & Johnson | 1 | $27 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Cormedix Inc. | 1 | $20 |
| Fresenius USA Marketing, Inc. | 1 | $19 |
| ANI Pharmaceuticals, Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Janssen Scientific Affairs, LLC | 1 | $15 |
| Novo Nordisk | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$15,175
- LOKELMA$14,379
- NXSTAGE SYSTEM ONE$124
- ACCRUFER$108
How this compares
$38,867 in reported general payments places this provider in the 95th percentile of 1,719 nurse practitioner providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 145 | $97,803 |
| LokelmaSodium Zirconium Cyclosilicate | 38 | $26,646 |
| KerendiaFinerenone | 27 | $25,550 |
| RayaldeeCalcifediol | 13 | $17,639 |
| JardianceEmpagliflozin | 26 | $16,858 |
| DapagliflozinDapagliflozin Propanediol | 11 | $5,871 |
| Calcitriol | 110 | $2,011 |
| Furosemide | 177 | $900 |
| Calcium Acetate | 11 | $576 |
| Losartan Potassium | 44 | $426 |
| Potassium Chloride | 39 | $411 |
| Allopurinol | 100 | $401 |
| Amlodipine Besylate | 59 | $327 |
| Bumetanide | 12 | $290 |
| Metoprolol Tartrate | 23 | $281 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $34,924 | $124,449183 claims |
| BayerKerendia | $775 | $25,55027 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $216 | $17,63913 claims |
| Boehringer IngelheimJardiance | $175 | $16,85826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,719 nurse practitioner providers in Arizona.
Other nurse practitioner in Phoenix
- Helena In't VeldPhoenix$64K
- Ryan MobleyPhoenix$22K
- Anita PalandriPhoenix$20K
- Kristina WernerPhoenix$19K
- Miranda IsomPhoenix$17K
- Catherine LynnPhoenix$16K
- Edith GazoPhoenix$15K
- Dora QuanPhoenix$14K
- Rachael BennettPhoenix$14K
- Marianne RosatiPhoenix$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.